FINE-TUNING T CELL NETWORKS OF EXHAUSTION BY SYNTHETIC SENSORS
T-FITNESS aims to enhance T cell therapy by preventing exhaustion through miRNA-based circuits and CRISPR/Cas editing, improving treatment efficacy for solid tumors in cancer patients.
Projectdetails
Introduction
Cell and gene therapies offer a massive paradigm shift from current treatment options and hold the potential to cure previously untreatable diseases. Naturally-occurring and genetically modified T cells with chimeric antigen (CAR) or T cell receptors (TCR) have demonstrated remarkable curative capacities against advanced hematologic malignancies but have shown limited efficacy in treating solid tumors.
Challenges in T Cell Therapy
Major barriers hindering the full antitumor potential of T cells are:
- The immunosuppressive signals within the tumor microenvironment
- Persisting antigenic stimuli that push T cells into a highly dysfunctional state called “exhaustion”
Proposed Solution: T-FITNESS
Herein, we propose a groundbreaking technology, T-FITNESS, which will enable antitumor T cells to become refractory to exhaustion.
Core Technology
At the core of the platform are microRNA (miRNA)-based synthetic logic circuits capable of rewiring the transcriptional networks orchestrating T cell exhaustion.
Integration with CRISPR/Cas
By harnessing the power of CRISPR/Cas genome editing, we will integrate sensors of miRNAs upregulated in exhausted cells into untranslated regions of one or more transcription factors driving T cell exhaustion, to enable their fine-tuned downregulation.
Validation and Development
We will validate the reprogramming efficacy of T-FITNESS by performing extensive functional analyses:
- In vitro
- In vivo
We will advance the best circuits towards the clinic by developing an automated cGMP-compliant manufacturing process for point-of-care production of T-FITNESS-edited CAR-T cells.
Collaborative Effort
To develop this innovative platform, we will bring together a multidisciplinary consortium of academic and industry partners that combine their unique expertise in:
- T cell therapy and immunology
- Synthetic biology
- Genome editing
- cGMP manufacturing
- Bioinformatics
- Communication
Impact on Cancer Treatment
Easily integrable within CAR-T, TCR-T, and tumor-infiltrating lymphocyte (TIL) platforms, T-FITNESS will unleash the curative potential of T cell therapy for the benefit of an ever-growing number of cancer patients.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 4.387.825 |
Totale projectbegroting | € 4.387.825 |
Tijdlijn
Startdatum | 1-9-2022 |
Einddatum | 31-8-2026 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- STIFTUNG LEIBNIZ-INSTITUT FUR IMMUNTHERAPIEpenvoerder
- FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
- CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
- FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA
- MILTENYI BIOTEC BV & CO KG
- INNOVATION ACTA SRL
- KEMIJSKI INSTITUT
- EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH
Land(en)
Vergelijkbare projecten binnen EIC Pathfinder
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
"Creation of innovative ""humidity to electricity"" renewable energy conversion technology towards sustainable energy challenge"The CATCHER project aims to develop scalable technology for converting atmospheric humidity into renewable electricity, enhancing EU leadership in clean energy innovation. | EIC Pathfinder | € 2.996.550 | 2022 | Details |
Quantitative Ultrasound Stochastic Tomography - Revolutionizing breast cancer diagnosis and screening with supercomputing-based radiation-free imaging.The project aims to revolutionize breast cancer imaging by developing adjoint-based algorithms for uncertainty quantification, enhancing diagnostic confidence through high-resolution, radiation-free images. | EIC Pathfinder | € 2.744.300 | 2022 | Details |
Dynamic Spatio-Temporal Modulation of Light by Phononic ArchitecturesDynamo aims to revolutionize imaging technologies by enabling simultaneous light modulation at GHz rates, enhancing processing speed and positioning Europe as a leader in optical advancements. | EIC Pathfinder | € 2.552.277 | 2022 | Details |
Emerging technologies for crystal-based gamma-ray light sourcesTECHNO-CLS aims to develop novel gamma-ray light sources using oriented crystals and high-energy particle beams, enhancing applications in various scientific fields through innovative technology. | EIC Pathfinder | € 2.643.187 | 2022 | Details |
"Creation of innovative ""humidity to electricity"" renewable energy conversion technology towards sustainable energy challenge"
The CATCHER project aims to develop scalable technology for converting atmospheric humidity into renewable electricity, enhancing EU leadership in clean energy innovation.
Quantitative Ultrasound Stochastic Tomography - Revolutionizing breast cancer diagnosis and screening with supercomputing-based radiation-free imaging.
The project aims to revolutionize breast cancer imaging by developing adjoint-based algorithms for uncertainty quantification, enhancing diagnostic confidence through high-resolution, radiation-free images.
Dynamic Spatio-Temporal Modulation of Light by Phononic Architectures
Dynamo aims to revolutionize imaging technologies by enabling simultaneous light modulation at GHz rates, enhancing processing speed and positioning Europe as a leader in optical advancements.
Emerging technologies for crystal-based gamma-ray light sources
TECHNO-CLS aims to develop novel gamma-ray light sources using oriented crystals and high-energy particle beams, enhancing applications in various scientific fields through innovative technology.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Polyclonal anti-tumor immunity by engineered human T cellsThis project aims to enhance adoptive T cell therapies for solid tumors by engineering TCR sensitivity and safety, creating robust, antigen-agnostic immune responses to improve patient outcomes. | ERC STG | € 1.812.500 | 2022 | Details |
Chimeric Antigen Receptor (CAR) T Cell Therapy For Solid TumorsCAR-T(uning) aims to enhance CAR-T therapy for NSCLC by improving treatment persistence and reducing tumor immunosuppression, paving the way for effective, broadly applicable cancer therapies. | ERC POC | € 150.000 | 2022 | Details |
Reversing T cell dysfunction in cancer by multimodal genetic screeningThis project aims to validate and characterize genes reversing T cell dysfunction in vivo to enhance immunotherapy effectiveness against cancer. | ERC ADG | € 2.499.375 | 2022 | Details |
Drivers and Brakes of CAR T Cell Efficacy Determined by the Tumor Immune MicroenvironmentThe CAR-TIME project aims to map the tumor immune microenvironment in lymphoma to enhance CAR T cell therapy efficacy and identify predictive biomarkers for patient response. | ERC STG | € 1.499.875 | 2024 | Details |
Polyclonal anti-tumor immunity by engineered human T cells
This project aims to enhance adoptive T cell therapies for solid tumors by engineering TCR sensitivity and safety, creating robust, antigen-agnostic immune responses to improve patient outcomes.
Chimeric Antigen Receptor (CAR) T Cell Therapy For Solid Tumors
CAR-T(uning) aims to enhance CAR-T therapy for NSCLC by improving treatment persistence and reducing tumor immunosuppression, paving the way for effective, broadly applicable cancer therapies.
Reversing T cell dysfunction in cancer by multimodal genetic screening
This project aims to validate and characterize genes reversing T cell dysfunction in vivo to enhance immunotherapy effectiveness against cancer.
Drivers and Brakes of CAR T Cell Efficacy Determined by the Tumor Immune Microenvironment
The CAR-TIME project aims to map the tumor immune microenvironment in lymphoma to enhance CAR T cell therapy efficacy and identify predictive biomarkers for patient response.